Renovaro Inc. (NASDAQ:RENB) Short Interest Up 27.7% in December

Renovaro Inc. (NASDAQ:RENB) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 3,870,000 shares, an increase of 27.7% from the November 30th total of 3,030,000 shares. Based on an average daily volume of 869,400 shares, the days-to-cover ratio is currently 4.5 days. Currently, 5.0% of the shares of the company are short sold.

Renovaro Stock Down 4.0 %

RENB traded down $0.04 during trading on Tuesday, hitting $0.84. 366,774 shares of the stock were exchanged, compared to its average volume of 628,313. Renovaro has a 1-year low of $0.40 and a 1-year high of $5.25. The stock has a fifty day moving average price of $0.91 and a two-hundred day moving average price of $0.91. The firm has a market capitalization of $132.61 million, a P/E ratio of -0.87 and a beta of 0.65.

Renovaro (NASDAQ:RENB) last announced its earnings results on Thursday, October 10th. The company reported ($0.45) EPS for the quarter.

Hedge Funds Weigh In On Renovaro

A number of large investors have recently bought and sold shares of RENB. Barclays PLC increased its stake in Renovaro by 315.7% in the 3rd quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after buying an additional 72,230 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Renovaro during the 2nd quarter worth $79,000. Bank of New York Mellon Corp purchased a new stake in shares of Renovaro in the 2nd quarter worth about $220,000. Finally, State Street Corp grew its stake in Renovaro by 3.8% in the 3rd quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after acquiring an additional 48,114 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.